Polyvalency (chemistry)

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

Retrieved on: 
Wednesday, October 12, 2022
U.S. Securities and Exchange Commission, Infection, CD8, RNA transfection, Exosome, MGH, CEPI, Virus, APC, Â, Vaccine, Immunity, Biology, Epitope, Research, Security (finance), Neuro-oncology, Partnership, Nasdaq, Private Securities Litigation Reform Act, Radio, Epidemic, Harvard University, Ragon Institute, RBD, MIT, Polyvalency (chemistry), GLOBE, Coalition, Antigen, Human, Poster, Coalition for Epidemic Preparedness Innovations, Pharmaceutical industry, Severe acute respiratory syndrome coronavirus 2, VOC

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced additional preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family. The data, which are being presented today in a presentation and poster at the Vaccines Summit 2022 in Washington, DC, demonstrate the potential of Codiak’s exoVACC™ vaccine candidate, exoRBD, to protect against multiple known Variants of Concern (VoC) of SARS-CoV-2 and seven coronaviruses from the Sarbecovirus family that are currently in bats and may have a high potential to jump into humans.

Key Points: 
  • Vaccine and therapeutic development for SARS-CoV-2 has been impressive and life-saving, but the virus continues to mutate to evade vaccine protection.
  • At the same time, there remains the threat that another beta coronavirus or variant of concern could emerge.
  • Its clear that a vaccine offering comprehensive immunity across a range of coronaviruses would address this urgent need and represents an important advancement in combatting these viruses, said Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak.
  • This suggests that our exosome-based vaccine could limit the virus ability to mutate and evade protection.

$185+ Bn Vaccine (Inactivated, Live Attenuated, Subunit Vaccines) Markets, 2028 by Indication, Route of Administration, Type, Valence - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 14, 2021
Health, Other Health, Organization, Government, Route of administration, Immunization, Monovalence, Immunity, Administration, COVID-19, Intramuscular injection, Growth, Industry, Streptococcus pneumoniae, Polyvalency (chemistry), COVID-19 vaccine, Vaccine, CAGR, Hepatitis, Prevalence, Coronavirus, Inactivated vaccine, Antigen, Inactivation, Pharmaceutical industry, Aquaculture, Rotavirus

The vaccine market's growth is mainly attributed to the high prevalence of diseases, technological advancements in the vaccines industry, increasing government initiatives towards immunization, and a strong pipeline for vaccines.

Key Points: 
  • The vaccine market's growth is mainly attributed to the high prevalence of diseases, technological advancements in the vaccines industry, increasing government initiatives towards immunization, and a strong pipeline for vaccines.
  • In addition, emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market.
  • However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.
  • Based on the disease indication, in 2021, the COVID-19 vaccines segment is estimated to account for the largest share of the total vaccines market.